Oceanpine Capital Investee Company——MingMed Biotechnology, a startup that develops pharmaceutical products, has completed raising nearly $50 million in its Series A+ round, the company announced on Monday.
New investors who participated in the said round are healthcare industry-focused Jifeng Ventures and Yifeng Capital, Oceanpine Capital, as well as Nasdaq-listed Chinese cosmetics e-commerce platform YSG. Returning investors – Gaorong Capital, JCP Capital, Flower City Ventures – re-upped in it.
MingMed has raised about $110 million in the last six months. It secured as much as $60 million in its Series A round in March this year from investors including Lightspeed China Partners, Gaorong Capital, state-backed Hengqin Financial Investment, Guangzhou-based Flower City Ventures and JCP Capital.
MingMed, headquartered in Guangzhou, was established in 2019. It has launched products for specialized areas like ophthalmology, small molecule immuno oncology, gene editing-based immunotherapy, medical aesthetics besides pet medicine.
Source: Oceanpine Capital
